Urogenital Neoplasms  >>  iniparib (BSI 201)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
iniparib (BSI 201) / Sanofi
NCT00677079: Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed
2
12
US
Iniparib, BSI-201, SAR240550
Sanofi
Primary Peritoneal Cancer, Advanced Epithelial Ovarian Cancer
12/08
12/08
NCT00687687: Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma

Completed
2
22
US
paclitaxel, carboplatin, BSI-201 (Iniparib), SAR204550
Sanofi, Gynecologic Oncology Group
Uterine Carcinosarcoma
03/10
12/11
NCT01033123: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Completed
2
41
US
BSI-201, PARP inhibitor
Sanofi
Ovarian Cancer
02/12
02/12
NCT01033292: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Completed
2
43
US
BSI-201, PARP inhibitor
Sanofi
Ovarian Cancer
12/12
12/12

Download Options